Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access June 1, 2011

Indapamide-induced hyponatremia or the syndrome of inappropriate antidiuretic hormone secretion: a case report

  • Jerzy Romaszko EMAIL logo , Ryszard Targonski , Leszek Cichowski and Janusz Sadowski
From the journal Open Medicine


We report a case of an apparently well-documented indapamide-induced hyponatremia. The initial diagnosis was made on the basis of dechallenge and rechallenge performed on two occasions. Further course of the disease, which proved inconsistent with our expectations, prompted us to look for another aetiology leading to the final diagnosis of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) complicated by indapamide treatment.

[1] Hannon M, Thompson C. SIADH: Prevalence, causes and consequences. Eur J Endocrinol. 2010; 162: S5–S12 in Google Scholar

[2] Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000; 342(21):1581–1589 in Google Scholar

[3] Biswas M, Davies JS. Hyponatremia in clinical practice. Postgrad Med J. 2007 Jun;83(980):373–378. Witek P. Progress in diagnosis and treatment of hyponatremia. Postepy Nauk Medycznych 2008; (2): 75–82 in Google Scholar

[4] Gill G, Leese G. Hyponatremia: biochemical and clinical perspectives. Postgrad Med J. 1998; 74(875):516–523 in Google Scholar

[5] Krysiak R, Okopień B. Carbamazepine-induced hyponatremia. Pol. Arch. Med. Wew. 2007; 117: 193–195 Search in Google Scholar

[6] Verbalis JG, Drutarosky MD, Ertel RJ, Vollmer RR. Adaptive responses to sustained volume expansion in hyponatraemic rats. J Endocrinol. 1989; 122(1):421–431 in Google Scholar

[7] Morledge JH. Clinical efficacy and safety of indapamide in essential hypertension. Am Heart J. 1983; 106(1 Pt 2):229–232 in Google Scholar

[8] PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287):1033–1041 in Google Scholar

[9] Piotrowski W, Włodarczyk P, Jasiński B, Rywik S. Efficacy and Acceptability of the Indapamide SR 1,5 mg (Tertensif® SR) in Patients above 55 Years of Age with Isolated Systolic Hypertension — the STIP Study. Nadciśnienie Tętnicze. 2001; 5(4): 245–252 Search in Google Scholar

[10] Leonetti G. Clinical positioning of indapamide sustained release 1.5mg in management protocols for hypertension. Drugs. 2000;59(Suppl 2):27–38; discussion 39–40 in Google Scholar

[11] Kuo SW, Pei-Dee, Hung YJ, Hsieh AT, Wu LY, Hsieh CH, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens. 2003;16(8):623–628 in Google Scholar

[12] Chapman MD, Hanrahan R, McEwen J, Marley JE. Hyponatremia and hypokalaemia due to indapamide. Med J Aust. 2002; 176(5):219–221 10.5694/j.1326-5377.2002.tb04377.xSearch in Google Scholar PubMed

[13] Hamano T, Yamamoto T, Miyamori I, Kuriyama M. Hyponatremia with somnolence due to indapamide. Rinsho Shinkeigaku. 2008;48(1):52–55 10.5692/clinicalneurol.48.52Search in Google Scholar PubMed

[14] Chan TY. Indapamide-induced severe hyponatremia and hypokalemia. Ann Pharmacother. 1995;29(11):1124–1128 10.1177/106002809502901111Search in Google Scholar PubMed

[15] Cabaj-Wiater I, Jakubowska I. Hyponatremia in Syndrome of Inappropiate Antidiuretic Hormone Secretion — cases report. Pol. Merk. Lek., 2008, 147: 247–249 Search in Google Scholar

[16] Howes L. Hyponatremia and hypokaliemia caused by indapamide. The medical Journal of Australia. 2002; 176(12): 53–54 10.5694/j.1326-5377.2002.tb04578.xSearch in Google Scholar PubMed

Published Online: 2011-6-1
Published in Print: 2011-8-1

© 2011 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 5.12.2023 from
Scroll to top button